# Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

> **NCT02883426** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
- **BIOLOGICAL:** H3N2v inactivated subvirion influenza vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02883426
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-01-05
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2018-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02883426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02883426, "Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02883426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*